Systematic Review
Accepted on 30 Sep 2025
First-line immune checkpoint inhibitors plus targeted therapy versus sorafenib or lenvatinib monotherapy for unresectable or advanced hepatocellular carcinoma: a meta-analysis of phase 3 trials
in Cancer Immunity and Immunotherapy
- 192 views